BI 1744-CL (Boehringer) shows positive results in Phase II COPD trial

A Phase II study shows that BI 1744-CL (olodaterol), from Boehringer, provides a significant increase in the lung function parameter FEV1 over a 24-hour period for patients with COPD. It found BI 1744-CL (5 microgram QD) provided significant improvement in lung function as measured by FEV1 AUC(0-12) versus twice-daily BI 1744-CL (2 microgram), while twice-daily dosing of BI 1744-CL (5 microgram) had a better FEV1 AUC(0-12) profile versus once-daily BI 1744-CL (10 microgram). There were no safety or tolerability concerns seen in the study. This data completes the BI 1744-CL monotherapy Phase II clinical trial program in patients with COPD and sets the stage for Phase III studies, says trial coordinator Professor Guy Joos, Head of the Department of Respiratory Diseases at Ghent University Hospital, Belgium. The data was presented at the 2012 Annual International Conference of the American Thoracic Society.